يعرض 1 - 5 نتائج من 5 نتيجة بحث عن '"Emily Y. Ye"', وقت الاستعلام: 1.00s تنقيح النتائج
  1. 1
    The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

    المؤلفون: Lauren Moran, Wei-Sheng Huang, Yaoyu Ning, Dong Zou, Scott Wardwell, Emily Y. Ye, Frank Wang, Rachel M. Squillace, Lindsey W. Eichinger, Victor M. Rivera, Jeff Keats, Sen Zhang, William C. Shakespeare, Yihan Wang, Sara Nadworny, Shuangying Liu, Tianjun Zhou, Youngchul Song, Xiaotian Zhu, Tim Clackson, David Miller, Hyun Gyung Jang, Narayana I. Narasimhan, Rana Anjum, David C. Dalgarno, Qurish K. Mohemmad, Juan J. Miret

    المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research. 22(22)

    مصطلحات موضوعية: 0301 basic medicine, Alectinib, Cancer Research, Lung Neoplasms, Brigatinib, medicine.drug_class, Pyridines, Antineoplastic Agents, Biology, 03 medical and health sciences, 0302 clinical medicine, Organophosphorus Compounds, Crizotinib, hemic and lymphatic diseases, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, medicine, ROS1, Anaplastic lymphoma kinase, Humans, Anaplastic Lymphoma Kinase, Sulfones, Protein Kinase Inhibitors, Ceritinib, ALK Gene Rearrangement, Receptor Protein-Tyrosine Kinases, Hep G2 Cells, U937 Cells, ALK inhibitor, 030104 developmental biology, Pyrimidines, Oncology, Biochemistry, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Mutation, Cancer research, Pyrazoles, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a954184cf0503cf7aa96ae269a34c3cb
    https://pubmed.ncbi.nlm.nih.gov/27780853

    أضف إلى المفضلة
  2. 2
    Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models

    المؤلفون: Biplab Das, Yun Zhang, Theresa E. Baker, Xiaotian Zhu, Emily Y. Ye, Meera Tugnait, Wei-Sheng Huang, Tianjun Zhou, Yongjin Xu, Narayana I. Narasimhan, Yaoyu Ning, Hyun Gyung Jang, William C. Shakespeare, David C. Dalgarno, Paul M. Taslimi, Scott Wardwell, Sen Zhang, Sara Nadworny, Victor M. Rivera, Francois Gonzalvez, Willmen Youngsaye, Anna Kohlmann, Feng Li, Gong Yongjin, Matthew T. Greenfield, Stephan G. Zech

    المصدر: Cancer Research. 76:2644-2644

    مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Mutation, Afatinib, Biology, Resistance mutation, medicine.disease_cause, Molecular biology, 03 medical and health sciences, Exon, T790M, 030104 developmental biology, 0302 clinical medicine, Gefitinib, Oncology, 030220 oncology & carcinogenesis, medicine, Erlotinib, Tyrosine kinase, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::cd3fc4ce5785604d73f92e73f1327360
    https://doi.org/10.1158/1538-7445.am2016-2644

    أضف إلى المفضلة
  3. 3
    Abstract 2827: Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants

    المؤلفون: Wei-Sheng Huang, Anna Kohlmann, Emily Y. Ye, Yaoyu Ning, Sen Zhang, Lisi Cai, Narayana I. Narasimhan, Feng Li, Tim Clackson, Xiaotian Zhu, David C. Dalgarno, Yongjin Xu, Victor M. Rivera, William C. Shakespeare, Scott Wardwell, Tianjun Zhou

    المصدر: Cancer Research. 75:2827-2827

    مصطلحات موضوعية: Cancer Research, biology, Oncogene, Crizotinib, medicine.drug_class, Chemistry, Pharmacology, medicine.disease, Receptor tyrosine kinase, ALK inhibitor, Fusion gene, Oncology, Protein kinase domain, hemic and lymphatic diseases, biology.protein, medicine, Anaplastic lymphoma kinase, Anaplastic large-cell lymphoma, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::373c083a07987e1adb50ddc2554ef367
    https://doi.org/10.1158/1538-7445.am2015-2827

    أضف إلى المفضلة
  4. 4
    Abstract 781: The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models

    المؤلفون: Scott Wardwell, Lindsey W. Eichinger, Biplab Das, Sen Zhang, J. Graeme Hodgson, Sara Nadworny, Victor M. Rivera, Emily Y. Ye

    المصدر: Cancer Research. 75:781-781

    مصطلحات موضوعية: Alectinib, Cancer Research, Ceritinib, Crizotinib, medicine.drug_class, business.industry, Cancer, medicine.disease, In vitro, Tyrosine-kinase inhibitor, ALK inhibitor, Oncology, In vivo, hemic and lymphatic diseases, medicine, Cancer research, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::be00c45056b3701a755ce367752a3b76
    https://doi.org/10.1158/1538-7445.am2015-781

    أضف إلى المفضلة
  5. 5
    Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)

    المؤلفون: John Iuliucci, Shuangying Liu, Victor M. Rivera, Wei-Sheng Huang, Frank Wang, Qurish K. Mohemmad, Tim Clackson, Juan J. Miret, Scott Wardwell, Narayana I. Narasimhan, David C. Dalgarno, Dung Yu Chun, Jeffrey A. Keats, Feng Li, Rana Anjum, Yaoyu Ning, Lauren Moran, Yihan Wang, William C. Shakespeare, Mathew Thomas, Emily Y. Ye, Sen Zhang

    المصدر: Cancer Research. 70:3623-3623

    مصطلحات موضوعية: Cancer Research, Chemistry, medicine.drug_class, ALK Gene Rearrangement, Cancer, Pharmacology, medicine.disease, ALK inhibitor, Oncology, In vivo, hemic and lymphatic diseases, medicine, Anaplastic lymphoma kinase, Potency, IC50, Anaplastic large-cell lymphoma

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::6510daf6d8b96f09c549f29f8dc91fc4
    https://doi.org/10.1158/1538-7445.am10-3623

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء